BiotechTube

Carbidopa/levodopa/entacapone

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Parkinson's Disease With End of Dose Wearing Off

Conditions

Parkinson's Disease With End of Dose Wearing Off

Trial Timeline

Jan 1, 2005 → Jul 1, 2008

NCT ID
NCT00219284

About Carbidopa/levodopa/entacapone

Carbidopa/levodopa/entacapone is a approved stage product being developed by Novartis for Parkinson's Disease With End of Dose Wearing Off. The current trial status is completed. This product is registered under clinical trial identifier NCT00219284. Target conditions include Parkinson's Disease With End of Dose Wearing Off.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00219284ApprovedCompleted

Competing Products

20 competing products in Parkinson's Disease With End of Dose Wearing Off

See all competitors
ProductCompanyStageHype Score
UB-312 + PlaceboVaxxinityPhase 1
25
NAV5001 + DaTscanNavidea BiopharmaceuticalsPhase 3
69
piclozotan + 0.9% sodium chloride (normal saline)Daiichi SankyoPhase 2
52
E2007EisaiPhase 3
77
ARICEPTEisaiPhase 3
77
PerampanelEisaiPhase 3
77
GPI 1485EisaiPhase 2
52
E2007EisaiPhase 3
77
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior PlaceboEisaiPhase 3
77
perampanel + placeboEisaiPhase 2
52
Lemborexant + placeboEisaiApproved
85
Placebo + E2007 + E2007EisaiPhase 3
77
E2007 + E2007 + E2007EisaiPhase 2
52
E2007EisaiPhase 2
52
E2007EisaiPhase 2
52
E2007EisaiPhase 2
52
2 mg perampanel + 4 mg perampanel + placebo comparatorEisaiPhase 3
77
Istradefylline (KW-6002)Kyowa KirinPhase 2
52
Istradefylline 20 mg or 40 mgKyowa KirinPhase 3
77
Istradefylline (KW-6002)Kyowa KirinPhase 3
77

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85